Clinical Trial Update: Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ION269 in participants with Down syndrome at risk for Alzheimer's…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Down Syndrome

Drugs mentioned

• ION269

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Alzheimer Disease, Down Syndrome | Phase 1 | Status: TERMINATED